-
Innovation Ranking
NewInnovation Ranking – Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company. The company develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company offer products such as Lialda, Mezavant, Mesavancol, and Uceris for the treatment of ulcerative colitis It also offers Eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.
-
Innovation Ranking
NewInnovation Ranking – Cosmo Energy Holdings Co Ltd
Cosmo Energy Holdings Co Ltd (Cosmo Energy Group) is an integrated oil company. It conducts exploration, production and marketing of oil products. The company produces and markets gasoline, naphtha, kerosene, diesel, fuel oil, crude oil, lubricants, LPG, asphalt, ethylene mixed-xylene, para-xylene, benzene, toluene and solvents, among others. It conducts these operations in Abu Dhabi, United Arab Emirates (UAE) and the State of Qatar. The company operates wind power and solar power generation facilities, has electricity distribution operation and operates Cosmo...
-
Company Insights
Innovation and Patenting activity of Cosmo Pharmaceuticals NV Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cosmo Pharmaceuticals NV Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of COSMOS Pharmaceutical Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of COSMOS Pharmaceutical Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Cosmo Chemical Co., Ltd. Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cosmo Chemical Co., Ltd. Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of Cosmo Energy Holdings Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Cosmo Energy Holdings Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-0311 in Androgenic Alopecia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-0311 in Androgenic Alopecia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-0311 in Androgenic Alopecia Drug Details: Clascoterone (CB-0311, Breezula) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Clascoterone in Androgenic Alopecia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Clascoterone in Androgenic Alopecia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Clascoterone in Androgenic Alopecia Drug Details: Clascoterone (Winlevi) is a cortexolone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Clascoterone in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Clascoterone in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Clascoterone in Triple-Negative Breast Cancer (TNBC) Drug Details: Clascoterone (Winlevi)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Glioblastoma Multiforme (GBM) Drug Details: Varlilumab (CDX-1127) is under...